VEGF nanoparticles repair the heart after myocardial infarction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 314, Issue 2, 2018, Pages H278-H284

  Oduk, Yasin ^a   Zhu, Wuqiang ^a   Kannappan, Ramaswamy ^a   Zhao, Meng ^a   Borovjagin, Anton V ^a   Oparil, Suzanne ^b   Jay Zhang, Jianyi ^a  

^a and Radiation Oncology   (United States)

^b University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

Cardiac tissue; Myocardial infarction; Nanoparticle; Revascularization; Sustained release; Vascular endothelial growth factor

Indexed keywords

NANOPARTICLE; POLYGLACTIN; RECOMBINANT VASCULOTROPIN; ANGIOGENIC FACTOR; DRUG CARRIER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B SCAN; BLOOD VESSEL PARAMETERS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG POTENCY; DRUG RELEASE; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; IMAGE ANALYSIS; IN VIVO STUDY; INTERNALIZATION; LOW DRUG DOSE; M MODE ECHOCARDIOGRAPHY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VASCULAR DENSITY; ANGIOGENESIS; ANIMAL; CELL CULTURE; CHEMISTRY; CONVALESCENCE; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECT; DRUG FORMULATION; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; NONOBESE DIABETIC MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; SCID MOUSE; TIME FACTOR; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELLS, CULTURED; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE, INBRED NOD; MICE, SCID; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RECOVERY OF FUNCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85043308515     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00471.2017     Document Type: Article

References (25)

1. Asmatulu R, Fakhari A, Wamocha HL, Chu HY, Chen YY, Eltabey MM, Hamdeh HH, Ho JC. Drug-carrying magnetic nanocomposite particles for potential drug delivery systems. J Nanotechnol 2009: 1–6, 2009. doi:10.1155/2009/238536.
2. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M, Schainfeld R, Isner JM. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132: 880–884, 2000. doi:10.7326/0003-4819-132-11-200006060-00005.
3. Brown RA, Phillips JB. Cell responses to biomimetic protein scaffolds used in tissue repair and engineering. Int Rev Cytol 262: 75–150, 2007. doi:10.1016/S0074-7696(07)62002-6.
4. Crafts TD, Jensen AR, Blocher-Smith EC, Markel TA. Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia. Cytokine 71: 385–393, 2015. doi:10.1016/j.cyto. 2014.08.005.
5. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72: 20–32, 2002. doi:10.1067/mcp.2002.126179.
6. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707–716, 2003. doi:10.1172/JCI17423.
7. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 136: 54–71, 2002. doi:10.7326/0003-4819-136-1-200201010-00011.
8. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5, Suppl 1: 37–44, 2000. doi:10.1634/theoncologist.5-suppl_1-37.
9. Groppa E, Brkic S, Bovo E, Reginato S, Sacchi V, Di Maggio N, Muraro MG, Calabrese D, Heberer M, Gianni-Barrera R, Banfi A. VEGF dose regulates vascular stabilization through semaphorin3A and the neuropilin-1+ monocyte/TGF-α1 paracrine axis. EMBO Mol Med 7: 1366–1384, 2015. doi:10.15252/emmm.201405003.
10. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER, Investigators V; VIVA Investigators. The VIVA trial: vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107: 1359–1365, 2003. doi:10.1161/01.CIR.0000061911.47710.8A.
11. Ho YT, Poinard B, Kah JC. Nanoparticle drug delivery systems and their use in cardiac tissue therapy. Nanomedicine (Lond) 11: 693–714, 2016. doi:10.2217/nnm.16.6.
12. Kadota S, Pabon L, Reinecke H, Murry CE. In vivo maturation of human induced pluripotent stem cell-derived cardiomyocytes in neonatal and adult rat hearts. Stem Cell Reports 8: 278–289, 2017. doi:10.1016/j. stemcr.2016.10.009.
13. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102: 898–901, 2000. doi:10.1161/01.CIR.102.8. 898.
14. Maharaj AS, D’Amore PA. Roles for VEGF in the adult. Microvasc Res 74: 100–113, 2007. doi:10.1016/j.mvr.2007.03.004.
15. Miquerol L, Gertsenstein M, Harpal K, Rossant J, Nagy A. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol 212: 307–322, 1999. doi:10.1006/dbio.1999.9355.
16. Rodness J, Mihic A, Miyagi Y, Wu J, Weisel RD, Li RK. VEGF-loaded microsphere patch for local protein delivery to the ischemic heart. Acta Biomater 45: 169–181, 2016. doi:10.1016/j.actbio.2016.09.009.
17. Simón-Yarza T, Tamayo E, Benavides C, Lana H, Formiga FR, Grama CN, Ortiz-de-Solorzano C, Kumar MN, Prosper F, Blanco-Prieto MJ. Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia. Int J Pharm 454: 784–790, 2013. doi:10.1016/j.ijpharm.2013.04.015.
18. Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA 99: 9656–9661, 2002. doi:10.1073/pnas. 152324099.
19. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90: II228–II234, 1994.
20. Xiong Q, Ye L, Zhang P, Lepley M, Swingen C, Zhang L, Kaufman DS, Zhang J. Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells. Circ Res 111: 455–468, 2012. doi:10.1161/CIRCRESAHA.112.269894.
21. Ye L, Chang YH, Xiong Q, Zhang P, Zhang L, Somasundaram P, Lepley M, Swingen C, Su L, Wendel JS, Guo J, Jang A, Rosenbush D, Greder L, Dutton JR, Zhang J, Kamp TJ, Kaufman DS, Ge Y, Zhang J. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 15: 750–761, 2014. doi:10.1016/j.stem.2014.11.009.
22. Zaruba MM, Zhu W, Soonpaa MH, Reuter S, Franz WM, Field LJ. Granulocyte colony-stimulating factor treatment plus dipeptidylpepti-dase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes. Eur Heart J 33: 129–137, 2012. doi:10.1093/eurheartj/ehr302.
23. Zhu W, Shou W, Payne RM, Caldwell R, Field LJ. A mouse model for juvenile doxorubicin-induced cardiac dysfunction. Pediatr Res 64: 488– 494, 2008. doi:10.1203/PDR.0b013e318184d732.
24. Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119: 99–106, 2009. doi:10.1161/CIRCULATIONAHA.108.799700.
25. Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M, Löhrs U. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153: 1425–1433, 1998. doi:10.1016/S0002-9440(10)65729-X.